The norm, in detail
Biological medicines: faster approval backed by reference agencies
ANMAT Provision 4351/2026 (Official Gazette, Jul 15, 2026)
in forceNATIONAL
Market deregulation
Disp. ANMAT 4351/2026 allows post-approval changes to vaccines and biologics to be assessed by relying on foreign reference agencies.
What changed and who it applies to
What changed
ANMAT approves 4 annexes with procedures for post-registration changes to BIOLOGICAL medicinal specialties (vaccines and biologics): safety/efficacy changes, quality changes (manufacturing, equipment, production sites), labeling information, and marketing-authorization extensions. It introduces an 'optimized reliance-based review procedure': to evaluate those changes, ANMAT can lean on evaluations already carried out by 'Reference Regulatory Authorities' (recognized foreign regulatory agencies), instead of repeating the full technical review from scratch. verif Jul 15, 2026 ↗
In force
Takes effect 30 business days after its publication in the Official Gazette (07/15/2026). verif Jul 15, 2026 ↗
Are you in or out?
Laboratories and marketing-authorization holders of biological medicines and vaccines in the REM (Registry of Medicinal Specialties) that need to process post-registration changes (manufacturing/site changes, safety/efficacy changes, labeling, marketing extensions). The reliance mechanism shortens the process when the change was already evaluated by a reference regulatory agency (e.g., FDA, EMA), instead of requiring a full technical review from scratch in Argentina. verif Jul 15, 2026 ↗
The norm
ANMAT Disposición 4351/2026 (DI-2026-4351-APN-ANMAT#MS), signed on Jul 14, 2026 and published in the Boletín Oficial on Jul 15, 2026 (notice 344377). verif Jul 15, 2026 ↗
Our reading
This is the same logic behind other procedural trims by the government, like the faster certification process in aviation (R4 · opening and deregulation): instead of requiring Argentina's regulator to redo an analysis a reference regulator already did, ANMAT leans on that work to resolve faster. It lowers the time (and cost) of keeping an already-approved biological product up to date in reference markets, without touching the required quality/safety/efficacy standard. thesis
Where it lands, province by province
Applies the same nationwide
No effect lands differently in any one province: it applies the same across the country.
The other rules on this subject39
The IGJ digitizes companies' financial statementsIGJ General Res. 9/2026 (RESOG-2026-9-APN-IGJ#MJ), Official Gazette Jul 2, 2026in force
Domestic trade: price-control and intervention rules fallRes. 12/2026 SIC (Official Gazette Jun 9, 2026)in force
Ley Hojarasca: cleanup of the legal framework (still in the Senate)Bill CD-1/26 (first-round approval May 20, 2026)pending
Ignacio Aredez· Chief analyst
Credentials and track record →- 10+ years in data science for clients across Europe and the Americas
- Certified in AI governance (ISO/IEC 42001)
- Machine Learning (Google Cloud)
- Registered expert with the European Commission
How to read the seals → verif primary source · prob primary source pending · unconf a source said it · estim our own calculation · thesis our reading · the date belongs to the datum, at the precision its source allows
Fact sheet built on the published rule, with the gaps declared. Back to the reforms
Write to us · free
Get on board the takeoff
Tell us what you are looking for and we will reply. This is what we work on: what this rule enables for you — which registry to join, what to certify and by when.
no spam
we reply within 48 business hours